Evidence map›Paper›PMID 35712517›Full record

ArticleFrontiers in oncology2022

High Expression of RECQL Protein in ER-Positive Breast Tumours Is Associated With a Better Survival.

Ardalan Mahmoodi, Ahmed Shoqafi, Ping Sun, Vasily Giannakeas, Cezary Cybulski, Sharon Nofech-Mozes, Jean-Yves Masson, Sudha Sharma, Amir Abbas Samani, Srinivasan Madhusudan and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 4 countries.

Ardalan MahmoodiWomen's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON, Canada.
Ahmed ShoqafiNottingham Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham, United Kingdom.
Ping SunWomen's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON, Canada.
Vasily GiannakeasWomen's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON, Canada.
Cezary CybulskiInternational Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, Szczecin, Poland.
Sharon Nofech-MozesSunnybrook Health Science Centre, University of Toronto, Toronto, ON, Canada.
Jean-Yves MassonGenome Stability Laboratory, Centre Hospitalier Universitaire (CHU) de Québec Research Center, Oncology Axis, Department of Molecular Biology, Medical Biochemistry and Pathology, Laval University Cancer Research Center, Québec, QC, Canada.
Sudha SharmaDepartment of Biochemistry and Molecular Biology, College of Medicine, Howard University, Washington, DC, United States.
Amir Abbas SamaniDepartment of Laboratory Medicine and Pathology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Srinivasan MadhusudanNottingham Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham, United Kingdom.
Steven A NarodWomen's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON, Canada.
Mohammad R AkbariWomen's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON, Canada.
University of Nottingham · GBUniversity of Toronto · CAWomen's College Hospital · CACentre hospitalier universitaire de Québec · CAHoward University · USHumber River Regional Hospital · CAPomeranian Medical University · PLPublic Health Ontario · CASunnybrook Health Science Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: RECQL (also known as RECQ1 and RECQL1) is a gene of recent interest in breast cancer and an association between high levels of RECQL protein in breast cancer tumour cells and good survival of patients has been reported. Methods: To validate this association, we measured the RECQL protein levels in tumours of 933 breast cancer patients using immunohistochemistry analysis and followed the patients for death from breast cancer. Results: Women with a level of RECQL protein above the 75th percentile had better 15-year disease-specific survival among ER-positive patients (62.5% vs. 48.7%, HR= 0.72, 95%CI= 0.52-0.98, p-value = 0.04), but not among ER- patients (48.9% vs. 48.0%, HR= 1.07, 95%CI= 0.67-1.69, p-value= 0.79). Among the ER-negative patients, high RECQL protein levels were associated with better survival among women who received tamoxifen treatment (67.0% vs. 51.5%, HR= 0.64, 95%CI= 0.41-0.99, p-value= 0.04). Conclusion: RECQL might be a new predictive marker for tamoxifen treatment among ER-positive patients.

Indexed as

breast cancerER-positiveexpressionRECQLsurvival

Identifiers

PMID35712517
PMCPMC9195420
OpenAlexW4281790913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.